Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy-Reference-Cited by-同舟云学术

Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy

Published:2023-07-07 Issue:1 Volume:55 Page:
ISSN:0785-3890
Container-title:Annals of Medicine
language:en
Short-container-title:Annals of Medicine

Author:

Qi Yao¹,Liu Hong²,Li Xin¹,Shi Yin²,Mu Juan¹,Li Jingyi¹,Wang Ying²^ORCID,Deng Qi¹^ORCID

Affiliation:

1. Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China

2. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Funder

Chinese Society of Clinical Oncology Beijing Xisike Clinical Oncology Research Foundation

The National Natural Science Foundation of China

Tianjin Municipal Science and Technology Commission Grant

The CAMS Innovation Fund for Medical Science

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/07853890.2023.2230888

Reference29 articles.